Search company, investor...
Diffusion Pharmaceuticals company logo

Diffusion Pharmaceuticals

diffusionpharma.com

Founded Year

2001

Stage

Reverse Merger | IPO

Total Raised

$35.03M

Market Cap

0.01B

Stock Price

5.99

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals is a clinical-stage company developing drugs which target the unmet medical needs characterized by oxygen deprivation (hypoxia) at the cellular level. These small molecules work by a mechanism of action that helps regulate the diffusion of oxygen selectively to hypoxic tissue. Potential breakthrough clinical applications include oncology, cardiovascular diseases, stroke and respiratory disorders. Diffusion's lead program is the use of TSC in the treatment of solid cancerous tumors. Published studies demonstrate a tripling of survival and superior tumor control when TSC is combined with radiation and chemotherapy in animal models of primary brain cancer. A phase 2 clinical study of TSC dosed concomitantly with radiation and chemotherapy in newly diagnosed GBM patients is currently enrolling patients.

Headquarters Location

2020 Avon Court Suite 4

Charlottesville, Virginia, 22902,

United States

434-220-0718

Missing: Diffusion Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Diffusion Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Diffusion Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Diffusion Pharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Diffusion Pharmaceuticals Patents

Diffusion Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Carotenoids
  • Oncology
  • Cyclohexenes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/9/2018

11/8/2022

Excipients, Carotenoids, Food additives, Cyclohexenes, Food colorings

Grant

Application Date

7/9/2018

Grant Date

11/8/2022

Title

Related Topics

Excipients, Carotenoids, Food additives, Cyclohexenes, Food colorings

Status

Grant

Latest Diffusion Pharmaceuticals News

LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals

Nov 17, 2022

GlobeNewswire Sets the Record Straight on Diffusions Misleading Narrative and Raises Concerns about a Troubling Pattern of Entrenchment and Lack of Accountability on the Board Has Nominated a Slate of Highly Qualified Directors NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- LifeSci Special Opportunities Master Fund Ltd. (LifeSci Special Opportunities or we), the holder of 96,976 shares of common stock of Diffusion Pharmaceuticals Inc. (Diffusion or the Company) (NASDAQ: DFFN), or approximately 4.8% of the Companys outstanding shares, today issued a statement in response to the Companys misleading press release from November 14, 2022 and announced that it has nominated a slate of high quality director candidates for election at the Companys upcoming annual meeting to be held on December 30, 2022 (the 2022 Annual Meeting). AD LifeSci Special Opportunities Statement The Companys November 14, 2022 press release announcing that its board of directors (the Board) has authorized a review and evaluation of potential strategic opportunities appears to have been deliberately timed in order to obscure prior attempts by third parties, including LifeSci Capital LLC (LS Capital), a commonly-owned affiliate of LifeSci Special Opportunities, acting on behalf of its clients, to engage the Board in discussions regarding potential strategic alternatives. The Companys press release endeavors to mislead stockholders regarding the facts as to LS Capitals efforts to constructively engage with the Company on possible pathways to unlock significant value for all of the Companys stockholders. Further, the announcement of the strategic review process appears to be a desperate and thinly veiled effort to distract stockholders and the market from the Companys failures, including the Boards and managements inability to develop their lead asset, Trans Sodium Crocetinate (TSC), and the catastrophic erosion of Diffusions cash balances and stockholder value that has occurred under their leadership. We believe that stockholders will be able to see through these transparent attempts to deflect attention away from the Companys operational and share price underperformance, including the fact that the Companys share price has declined by approximately 78% from November 15, 2021 to November 11, 2022.1 We encourage stockholders to review our proxy materials as they become available, which will include additional information regarding our concerns with the Company. Background Information On October 17, 2022, on behalf of a client and unaffiliated investor in the Company, LS Capital presented an unsolicited offer to the Company to purchase 100% of the Companys outstanding common stock not already owned by its client for $6.58 per share in cash, which represented a 20% premium to the Companys closing stock price as of the close of business on Friday, October 13, 2022. The Company unceremoniously rejected the offer on October 25, 2022. AD AD Since May 2022, LS Capital had attempted to engage constructively with the Company on behalf of LS Capitals client to discuss potential strategic alternatives that LS Capital believed would be in the Companys best interest and unlock value for all of the Companys stockholders. Following LS Capitals initial contact, the Company ignored all attempts by LS Capital to continue engaging for nearly four months until mid-September. With the Board and management continuing to refuse to engage directly, LS Capital had the opportunity to speak with an investor relations firm representing the Company, and continued to request to speak with Diffusions management. As a precursor to a call with management, LS Capital discussed entering into a non-disclosure agreement with the Company. However, the Companys proposed non-disclosure agreement was far from customary in LS Capitals experience and sought to impose a multi-year standstill and other burdensome restrictions, which LS Capital viewed as a deliberate and troubling attempt by the Board to disenfranchise stockholders and further ensconce themselves in Diffusions failing business. Ultimately, a call with the Company proceeded without a non-disclosure agreement in place, and LS Capital shared its thoughts with the Company on potential strategic options. Following this call, the Company ceased engaging with LS Capital, refusing requests for follow-up discussions and negotiations. Not surprisingly, the Companys behavior appears to be consistent with its vague October 25, 2022 press release, which stated There is no timeline for this review and there is no assurance that the Boards review will result in any transaction being consummated. Diffusion does not intend to comment on the process or make further disclosures until it determines an update is appropriate. LifeSci Special Opportunities, as a large stockholder of the Company, is naturally concerned about the Boards motives and willingness to actually engage in substantive conversations that, in our view, would result in the Company achieving its stated goal of enhancing shareholder value. LifeSci Special Opportunities is also concerned that the Company has not held an annual meeting to elect directors in nearly 17 months, which appears to be yet another entrenchment tactic by the Board to maintain the status quo. When the 2022 Annual Meeting of stockholders is finally held (assuming the Company does not delay it again), it will be over 18 months since directors were elected at the 2021 annual meeting of stockholders. Furthermore, it appears the Company only announced that it would hold the 2022 Annual Meeting as a reactive measure to external pressure, such as the third party offer from LS Capitals client, and did so with very little notice, which prompted an accelerated timeline for stockholders to provide notice of any nominations or business proposals. The timing of the Companys public announcement of its strategic review process also seems to be only in response to the unsolicited offer to acquire the Company rather than any genuine initiative by leadership to take actions that are in the best interest of Diffusion stockholders. We also question the circumstances surrounding the recent and abrupt weekend-resignation of one of the Companys directors that was announced concurrently with the Companys misleading press release. AD AD In LifeSci Special Opportunities view, these are all clear and unfortunate symptoms of a reactive and troubled Board that is trying to avoid being held accountable by its stockholders. The Urgent Need for Fresh Perspectives Given the Boards track record of overseeing significant value destruction and seeming indifference towards the Companys stockholders, the true owners of the Company, we believe it has become abundantly clear that the current Board and management are not worthy stewards of our Company. We have serious concerns about whether they can be trusted to run the strategic review process, especially given their entrenchment tactics and the timing of the stated commencement of the review process, which appears to only have been undertaken in response to an unsolicited offer. While we are open to working constructively with the Company, we do not intend to stand idly by and allow the Board and management to continue unchecked on this path of value destruction. To that end, we have nominated the following highly qualified individuals for election at the 2022 Annual Meeting: Jill Davidson Ms. Davidson has significant expertise in the pharmaceutical industry and currently serves as the President of Fast Scripts LLC, an early-stage medical service provider to those recovering from opioid addiction Previously, Ms. Davidson served in c-suite level roles at medical care providers Omnicare, Inc. and Clasen Long Term Care Pharmacy. She was also the President of the Missouri-Illinois Gateway Hemophilia Association and the Vice President of the National Pharmacy Roundtable. Ms. Davidson is the Co-Manager of SkiProp LLC and the Manager of Davidson LLC, which both own various rental properties. Tenzin Khangsar Mr. Khangsar is the Principal at Snowlion Ventures, a Vancouver-based financial consulting firm, and was previously an advisor to Deloitte Touche and a Managing Director and Executive Vice President for RCI Capital Group. Mr. Khangsar has served as an executive advisor for privately-held emerging growth companies and publicly-traded corporations alike, advising on financial strategy and execution and organizational infrastructure to support governance matters, among which include Google LLC, Key, Empower Clinics Inc. and Dapper Labs. Mr. Khangsar also previously served in various government roles in Canadas Office of the Prime Minister and the Minister of Immigration, including as Chief of Staff, and served as Honorary Counsel to the Government of Mongolia, Chair of the Multicultural Advisory Committee of British Columbia and Director and President of the Canada-India Business Council. He also previously served on the board of directors of Northstar Trade Finance, a financial services provider, and Planterra, a non-profit dedicated to sustainable community development through travel, and has significant experience serving in executive roles at non-profit organizations. AD Jeffrey Kimbell Mr. Kimbell has extensive experience in the healthcare industry as well as significant advisory and government experience, and he currently serves as the President of Jeffrey J. Kimbell & Associates, a client service provider to the life sciences industry. Mr. Kimbell served on President George W. Bushs Transition Team Advisory Committee for the U.S. Department of Health and Human Services. Previously, he served as Founding Partner of Advyzom, LLC, a leading boutique consulting company specializing in highly strategic regulatory and development advice and services for the pharmaceutical and healthcare industries. Mr. Kimbell previously served as the first Executive Director of the Medical Device Manufacturers Association, one of the leading educational and advocacy association advancing the interests of innovative and entrepreneurial medical device manufacturers in the United States. Jessica M. Lockett Ms. Lockett currently serves as a Partner at Lockett + Horwitz, PLC. Ms. Lockett has extensive knowledge of the capital markets and securities laws, and as a corporate and securities law attorney, she has experience representing public and private companies at various stages of development with corporate governance and securities matters, as well as advising on mergers and acquisitions, financing, and fundraising activities. Ms. Lockett currently serves on the board of directors of Ammo, Inc. (NASDAQ: POWW). Jeffrey Max Mr. Max has extensive experience as a c-suite level executive across a variety of industries. He currently serves as the CEO of Ascent Solar Technologies, and previously served as CEO of Agile Space Industries, Inc., Rezolve, Inc., Venda, Inc. and WhiteLight Systems, Inc., and as President of Powa Technologies, Inc. Mr. Max currently serves as a director of Orbital Assembly Corporation. Mr. Max previously served as a Managing Partner of La Plata Capital Partners, LLC, and as a Senior Advisor to Liiv Group, two investment-based companies. Mr. Max also previously served as Managing Director PLR Advisors, Ltd., a capital markets and technology consulting firm, and Executive Vice President of OptiMark Technologies Inc., a stock-trading technology developer. AD John Ziegler MD Dr. Ziegler is currently the Chief Medical Officer of Promedim Ltd., a firm specializing in the oversight of pharmaceutical clinical trials, and also serves as the Managing Partner of Mountain Anesthesia PLLC (d/b/a Premier Healthcare Partners). Dr. Ziegler has served as a consultant to the pharmaceutical industry since 2012 and, in that capacity, has acted as the Medical Director of many clinical trials and drug development programs for a number of pharmaceutical companies and clinical research organizations, and is also a Fellow of the American Society of Anesthesiologists. Dr. Ziegler previously served on the board of directors of LifeSci Acquisition Corp. About LifeSci Special Opportunities Master Fund Ltd. Formed in 2021, LifeSci Special Opportunities is a public investing arm of LifeSci Partners, a unique life sciences and healthcare consultancy formed in 2010. The fund invests within the public healthcare industry focusing on undervalued biotech and pharmaceutical companies. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS LifeSci Special Opportunities Master Fund Ltd., a Cayman Islands exempted company (LifeSci Special Opportunities), together with the other participants named herein (collectively, LifeSci), intends to file a preliminary proxy statement and accompanying universal proxy card with the Securities and Exchange Commission (SEC) to be used to solicit votes in connection with the 2022 annual meeting of stockholders of Diffusion Pharmaceuticals Inc., a Delaware corporation (the Company). LIFESCI STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SECS WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR. AD AD The participants in the proxy solicitation are anticipated to be LifeSci Special Opportunities, LifeSci Special Opportunities Partners LP, a Delaware limited partnership (LifeSci Opportunities Partners), LifeSci Special Opportunities Offshore Fund, Ltd., a Cayman Islands exempted company (LifeSci Offshore), LifeSci Special Opportunities Partners GP, LLC, a Delaware limited liability company (LifeSci GP), LifeSci Management Company LLC, a Delaware limited liability company (LifeSci Management), David Dobkin, Jill Davidson, Tenzin Khangsar, Jeffrey Kimbell, Jessica M. Lockett, Jeffrey Max and John S. Ziegler. As of the date hereof, LifeSci Special Opportunities beneficially owns 96,976 shares of common stock, $0.001 par value per share, of the Company (the Common Stock). LifeSci Opportunities Partners, as a feeder fund of LifeSci Special Opportunities, may be deemed to beneficially own the 96,976 shares of Common Stock beneficially owned by LifeSci Special Opportunities. LifeSci Offshore, as a feeder fund of LifeSci Special Opportunities, may be deemed to beneficially own the 96,976 shares of Common Stock beneficially owned by LifeSci Special Opportunities. LifeSci GP, as the general partner of LifeSci Special Opportunities, may be deemed to beneficially own the 96,976 shares of Common Stock beneficially owned by LifeSci Special Opportunities. LifeSci Management, as the investment manager of LifeSci Special Opportunities, may be deemed to beneficially own the 96,976 shares of Common Stock beneficially owned by LifeSci Special Opportunities. Mr. Dobkin, as managing member of each of LifeSci GP and LifeSci Management, may be deemed to beneficially own the 96,976 shares of Common Stock beneficially owned by LifeSci Special Opportunities. As of the date hereof, none of Messes. Davidson and Lockett or Messrs. Khangsar, Kimbell, Max and Ziegler own beneficially or of record any securities of the Company. 1 Represents the date one trading day prior to LifeSci Special Opportunities engagement with the Company becoming public. AD

Diffusion Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Diffusion Pharmaceuticals Rank

Diffusion Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Diffusion Pharmaceuticals founded?

    Diffusion Pharmaceuticals was founded in 2001.

  • Where is Diffusion Pharmaceuticals's headquarters?

    Diffusion Pharmaceuticals's headquarters is located at 2020 Avon Court, Charlottesville.

  • What is Diffusion Pharmaceuticals's latest funding round?

    Diffusion Pharmaceuticals's latest funding round is Reverse Merger.

  • How much did Diffusion Pharmaceuticals raise?

    Diffusion Pharmaceuticals raised a total of $35.03M.

  • Who are the investors of Diffusion Pharmaceuticals?

    Investors of Diffusion Pharmaceuticals include Restorgenex Corporation and U.S. Office of Naval Research.

  • Who are Diffusion Pharmaceuticals's competitors?

    Competitors of Diffusion Pharmaceuticals include Arena Pharmaceuticals, ISA Pharmaceuticals, Sequel Pharmaceuticals, Pulmatrix, Elevation Pharmaceuticals and 11 more.

Compare Diffusion Pharmaceuticals to Competitors

K
Kytogenics Pharmaceuticals Limited

Kytogenics is a medical device company. It had developed the Nocc Hydrophilic Wound Dressing.Kytogenics Pharmaceuticals, Inc. is a biomedical company engaged in the development of products based on its medical device and drug delivery patented platform technology.

E
ENTRA Pharmaceuticals

ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.

N
NanoMedex Pharmaceuticals

NanoMedex uses patented formulation strategies to dissolve drugs in water that are only soluble in fats or lipids. Once dissolved in water, these drugs can be administrated intravenously. In hospitals, intravenous administration is preferred by older patients to eliminate swallowing, by physicians to increase certainty that the correct drug dose is given, and by health care providers to ensure that Medicare reimburses 100 percent of costs (versus 50 percent for oral administration).

A
Ancora Pharmaceuticals

Ancora Pharmaceuticals aims to enable synthetic carbohydrate-based product discovery and development utilizing its carbohydrate synthesis capability, which is based on technology originally developed at the Massachusetts Institute of Technology (M.I.T.). The company is applying its synthesis technology both to internal drug development programs and strategic collaborations within the pharmaceutical and biotechnology sector.

A
Advent Pharmaceuticals

Advent Pharmaceuticals is a specialty pharmaceutical company focused on developing inhaled drug products using a dry powder inhalation delivery system. The products are mostly used for the treatment of asthma and other respiratory diseases.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.